JDRF, the world’s leading nonprofit organization funding type 1 diabetes (T1D) research, is spearheading efforts to tailor closed-loop insulin delivery systems specifically for pregnant women with T1D. Pregnancy introduces profound physiological changes that dramatically alter glucose metabolism, making it one of the most challenging periods for women living with T1D. Despite advances in insulin pump therapy and continuous glucose monitors (CGM), many pregnant women still struggle to maintain blood glucose levels within the narrow target ranges required to protect both maternal and fetal health. JDRF’s targeted investment in closed-loop technology—often referred to as the artificial pancreas—aims to automate insulin delivery, reduce the cognitive burden of self-management, and ultimately improve outcomes for this high-risk population.

Understanding Closed-Loop Systems: How They Work

Closed-loop systems combine three core components: a continuous glucose monitor (CGM), an insulin pump, and a control algorithm running on a dedicated device or smartphone app. The CGM measures interstitial glucose levels every 5 to 15 minutes and transmits the data wirelessly to the algorithm. The algorithm calculates the optimal insulin dose needed to keep glucose within a predefined target range and commands the pump to deliver that dose automatically.

The goal is to create a “closed loop” that mimics the feedback control of a healthy pancreas. Current systems are typically “hybrid” closed loops, meaning that while the algorithm handles background insulin adjustments, users still need to announce meals and—in some cases—capillary glucose confirmations. Advanced algorithms use predictive models to anticipate changes before they occur, allowing for rapid corrections that are especially valuable during pregnancy when hormonal surges can cause swift glucose excursions.

Why Pregnancy with T1D Demands a Specialized Solution

Pregnancy induces insulin resistance, a condition where the body’s cells become less responsive to insulin. This occurs primarily in the second and third trimesters due to increased placental secretion of hormones such as human placental lactogen, estrogen, progesterone, and cortisol. For women with T1D, whose pancreas produces no native insulin, this resistance forces them to increase their insulin doses dramatically—often by 200% to 300% above pre-pregnancy baselines. Simultaneously, the risk of hypoglycemia remains elevated, especially during the first trimester and after delivery.

Standard automated insulin delivery systems are typically designed for non-pregnant adults and may not respond appropriately to the rapid, hormone-driven glycemic shifts seen during gestation. For instance, many algorithms target a fasting glucose range of 100–120 mg/dL, whereas pregnancy guidelines recommend 60–99 mg/dL for optimal fetal outcomes. JDRF recognizes that off-the-shelf solutions fall short, which is why it is funding the development of algorithms and hardware specifically optimized for the pregnant state.

JDRF’s Strategic Role: Funding, Partnerships, and Advocacy

JDRF has a long history of supporting groundbreaking T1D research, and its commitment to pregnancy-specific closed-loop systems is no exception. Through its JDRF Translational Research Division, the organization awards grants to academic institutions, startups, and established medical device companies that are working on adaptive algorithms, improved sensor accuracy, and user-friendly interfaces for pregnant women.

One notable initiative is the JDRF Pregnancy in T1D Consortium, a collaborative network that brings together clinicians, engineers, and data scientists to accelerate the development of technologies that meet the unique needs of this population. The consortium also facilitates multi-center clinical trials, ensuring that systems are tested in real-world settings with diverse patient demographics. Additionally, JDRF advocates with regulatory agencies such as the FDA to streamline approval pathways for devices that target pregnancy, recognizing the urgency of making these tools available to women who need them now.

External collaborations extend to organizations like the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA), where JDRF co-funds research symposia focused on maternal-fetal health. These partnerships amplify the urgency and ensure that closed-loop pregnancy research remains a priority on the global diabetes agenda.

Key Initiatives and Grants

  • Algorithm Adaptation Grants: Funding teams developing machine-learning models that detect early trimester changes and adjust insulin delivery baselines accordingly.
  • Sensor Reliability Studies: Supporting research into CGM accuracy during pregnancy, where edema, altered blood flow, and interstitial fluid composition can affect sensor performance.
  • Clinical Validation Programs: Sponsoring randomized controlled trials comparing closed-loop therapy to standard of care in pregnant women with T1D, with endpoints including time-in-range, HbA1c, and neonatal outcomes.
  • User-Centered Design: Investing in qualitative research to understand the barriers and preferences of pregnant women, ensuring that systems are not only safe but also practical and unobtrusive.

Research and Development Goals: Precision and Adaptability

The research goals that JDRF supports are granular and ambitious. Beyond the general aim of improving maternal and fetal health, specific technical targets include:

  • Enhancing sensor accuracy during periods of rapid glucose change: Pregnancy can trigger 50–100 mg/dL swings within 30 minutes. Current CGMs have a mean absolute relative difference (MARD) of around 10%, but pregnancy-specific challenges require MARD below 8% to prevent over- or under-correction.
  • Developing algorithms that account for renal function and insulin clearance changes: Pregnant women experience increased glomerular filtration rate and faster insulin clearance; algorithms must incorporate predictive models to offset these pharmacokinetic shifts.
  • Real-time adaptation to insulin resistance: The algorithm should automatically detect rising resistance patterns and adjust the basal rate and insulin-to-carbohydrate ratios without user intervention.
  • Integration with postpartum management: After delivery, insulin resistance drops rapidly, increasing hypoglycemia risk. Systems must smoothly transition from pregnancy to postpartum settings, ideally without requiring recalibration.
  • Safety features for hypoglycemia during sleep and exercise: Pregnant women often have overnight hypoglycemia; closed-loop systems need robust prediction thresholds that trigger low-glucose suspend or adjust basal rates preemptively.

Algorithm Architecture

The control algorithms under development range from proportional-integral-derivative (PID) controllers to model predictive control (MPC) and fuzzy-logic systems. MPC is particularly promising for pregnancy because it uses a mathematical model of the user’s glucose dynamics to predict future glucose levels up to 60 minutes ahead. By incorporating pregnancy-specific parameter sets—such as trimester-specific insulin sensitivity factors—MPC can preemptively modulate insulin delivery. JDRF has funded work at several universities, including the University of Cambridge’s CamAPS platform, which has shown excellent results in non-pregnant adults and is now being adapted for pregnancy studies.

Clinical Trials and Real-World Evidence

The translation of these technologies from bench to bedside is already underway. JDRF has supported several pivotal trials, including the Closed-Loop in Pregnancy Study (CLIP) and the Artificial Pancreas for Pregnancy (AP-PREGN) multicenter trial. Preliminary data from these studies demonstrate that hybrid closed-loop systems can increase time-in-target range (63–140 mg/dL during pregnancy) by 15–25 percentage points compared to sensor-augmented pump therapy alone. Moreover, the incidence of severe hypoglycemic events was reduced by nearly half in closed-loop groups.

One notable system, the iLet Bionic Pancreas (developed by Beta Bionics), has been evaluated in pregnancy sub-studies. The iLet uses a bihormonal approach—insulin and glucagon—which could theoretically offer greater protection against hypoglycemia. While glucagon during pregnancy raises separate safety questions (e.g., risk of nausea or vomiting), preliminary findings are encouraging and JDRF continues to support further investigation.

In addition, JDRF has contributed to the development of the Dana Diabecare RS and Omnipod 5 platforms by funding algorithm validation studies that include pregnant women. Such studies are essential because algorithm performance can vary significantly between devices, and JDRF’s role as a neutral funder helps generate unbiased evidence for clinical adoption.

For those interested in following ongoing research, the ClinicalTrials.gov database lists multiple JDRF-funded trials under the keywords “closed-loop pregnancy type 1 diabetes.” The agency’s rigorous oversight ensures that safety endpoints—including maternal hypoglycemia, neonatal hypoglycemia, and incidence of large-for-gestational-age (LGA) infants—are systematically collected.

Impact on Maternal and Fetal Health

The ultimate goal of JDRF’s closed-loop investment is to improve outcomes for both mother and child. T1D during pregnancy is associated with a significantly increased risk of preeclampsia, cesarean delivery, preterm birth, and neonatal complications such as macrosomia (excessive birth weight), respiratory distress, and jaundice. Long-term, children born to mothers with T1D have a higher risk of metabolic disorders later in life.

Evidence from early closed-loop trials shows that tighter glycemic control reduces the incidence of macrosomia by up to 30% compared to conventional therapy. Birth weights shift closer to the 50th percentile, and neonatal intensive care unit admissions decrease. For mothers, improved time-in-range correlates with lower rates of hypertensive disorders and fewer cases of severe hypoglycemia requiring third-party assistance. JDRF’s support is therefore not just about convenience—it is about saving lives and reducing healthcare costs associated with high-risk pregnancies.

Beyond direct health metrics, closed-loop systems alleviate the immense mental burden of managing T1D during pregnancy. Women report constant worry about glucose levels affecting their baby, leading to sleep deprivation and anxiety. By automating insulin adjustments, closed-loop systems free up cognitive resources, allowing women to focus on the joys and challenges of pregnancy itself. JDRF’s commitment to user-centered design ensures that these systems are developed with input from mothers, nurses, and endocrinologists, making them more likely to be adopted in routine care.

Future Directions: Toward Fully Autonomous Systems

JDRF’s vision extends beyond hybrid closed loops. The organization is investing in next-generation technologies that could one day allow for fully autonomous insulin delivery during pregnancy, eliminating the need for meal announcements and capillary calibrations. This requires advancements in ultra-fast insulin analogs, dual-hormone pumps, and sensor technology that can detect meal ingestion via gastrointestinal biomarkers.

Another frontier is the integration of biometric data from wearable devices—such as heart rate variability, skin temperature, and accelerometry—to provide contextual cues for the algorithm. For example, an increased heart rate and skin temperature could signal adrenal activation from a hypoglycemic counter-regulatory response, prompting preemptive insulin reduction. JDRF has partnered with digital health companies like Dexcom and Insulet to explore these possibilities.

Finally, JDRF is actively working to ensure equity in access. Commercial closed-loop systems can cost thousands of dollars, and insurance coverage for pregnancy-specific versions is currently inconsistent. Through advocacy, JDRF pushes for Medicare and private payers to recognize closed-loop therapy as the standard of care during pregnancy, thereby reducing financial barriers for all women, regardless of socioeconomic status.

Conclusion

JDRF’s focused support for closed-loop systems designed for pregnant women with type 1 diabetes represents a transformative shift in obstetric diabetes care. By funding algorithm innovation, sensor refinement, and rigorous clinical trials, the organization is bridging the gap between general-purpose diabetes technology and the specialized needs of gestation. The early results are promising—improved glycemic control, fewer complications, and enhanced quality of life for mothers-to-be. As JDRF continues to drive research, expectant women with T1D can look forward to a future where advanced automation makes pregnancy safer and more manageable. For more information on JDRF’s initiatives, visit JDRF’s official website and explore their pregnancy and T1D resource page. To learn about the latest studies, refer to the American Diabetes Association’s pregnancy guidelines and PubMed’s growing collection of peer-reviewed articles on closed-loop technology in pregnancy.